CAPS2 Activators

Chemical activators of CAPS2 enhance its function in vesicle trafficking and neurotransmitter release by various means. Phorbol 12-myristate 13-acetate (PMA) serves as an activator of protein kinase C (PKC), which can lead to the phosphorylation of CAPS2, thereby facilitating its role in synaptic vesicle priming and exocytosis. Similarly, Forskolin raises intracellular cAMP levels, subsequently activating protein kinase A (PKA), which is known to phosphorylate proteins like CAPS2, thereby enhancing its activation. Ionomycin and A23187, both calcium ionophores, increase intracellular calcium levels, a key player in the activation of CAPS2, as it is crucial for calcium-dependent exocytosis. Additionally, Brefeldin A disrupts the structure and function of the Golgi apparatus, which may indirectly result in the enhanced activity of CAPS2 due to increased demands for vesicle trafficking and recycling.

Thapsigargin, by inhibiting SERCA pumps, elevates cytosolic calcium, which can lead to the activation of CAPS2, as it is implicated in the calcium-mediated vesicle release process. Analogous to Thapsigargin, N6-Benzoyladenosine-3',5'-cyclic monophosphate and Dibutyryl-cAMP are cAMP analogs that stimulate PKA, which can phosphorylate and activate CAPS2. DiC8, a synthetic analog of diacylglycerol, activates PKC, potentially resulting in the phosphorylation and activation of CAPS2. Okadaic Acid and Calyculin A both inhibit protein phosphatases PP1 and PP2A, which may prevent the dephosphorylation of CAPS2, maintaining it in an activated state. Finally, Phosphatidylserine, a component of the vesicle membrane, can influence the membrane dynamics and signaling pathways that are conducive to CAPS2 activation, underlining its importance in the functional regulation of vesicle fusion.